Results 41 to 50 of about 86,041 (135)

Impact of drug therapy on the risk of death in patients with coronary heart disease (according to the data of registry of cardiovascular diseases, RECVASA) [PDF]

КардиоСоматика, 2017
The aim of the study was to evaluate the effect of the drug therapy assigned at the index visit on the risk of fatal outcome in outpatients with coronary heart disease within 24 months from the index visit, based on the data of registry of cardiovascular
K. G Pereverzeva, S. S Yakushin, A. N Vorobyev, M. M Lukyanov, E. Yu Andreyenko, A. V Zagrebelny, A. D Deev   +6 more
doaj  

Structural and molecular basis of angiotensin-converting enzyme by computational modeling: Insights into the mechanisms of different inhibitors.

PLoS ONE, 2019
Angiotensin-I converting enzyme (ACE) is a two-domain dipeptidylcarboxypeptidase involved in regulating blood pressure via the kallikrein-kininand renin-angiotensin-aldosterone complex.
Li Fang, Mingxian Geng, Chunlei Liu, Ji Wang, Weihong Min, Jingsheng Liu   +5 more
doaj   +1 more source

The Potential Effects of ACE Inhibitors on the Severity of Periodontal Disease-Related Attachment Loss: An Observational, Cross-Sectional Comparative Study

Oral
Background/Objectives: Angiotensin-converting enzyme (ACE) inhibitors are commonly prescribed anti-hypertensive agents. However, one of their effects is reducing the breakdown of a number of pro-inflammatory mediators, including bradykinin and substance ...
Kathrine Cullinan, Monika Behrens, Kylie Del Solar, Kimberley Johnson, Andrea James, Brian James, Alan Nimmo   +6 more
doaj   +1 more source

Angiotensin-I-Converting Enzyme (ACE) Inhibitors from Marine Resources: Prospects in the Pharmaceutical Industry

Marine Drugs, 2010
Hypertension or high blood pressure is one of the major independent risk factors for cardiovascular diseases. Angiotensin-I-converting enzyme (EC 3.4.15.1; ACE) plays an important physiological role in regulation of blood pressure by converting ...
Isuru Wijesekara, Se-Kwon Kim
doaj   +1 more source

Carriers of Heterozygous Loss-of-Function ACE Mutations Are at Risk for Alzheimer’s Disease

Biomedicines
We hypothesized that subjects with heterozygous loss-of-function (LoF) ACE mutations are at risk for Alzheimer’s disease because amyloid Aβ42, a primary component of the protein aggregates that accumulate in the brains of AD patients, is cleaved by ACE ...
Sergei M. Danilov, Ivan A. Adzhubei, Alexander J. Kozuch, Pavel A. Petukhov, Isolda A. Popova, Ananyo Choudhury, Dhriti Sengupta, Steven M. Dudek   +7 more
doaj   +1 more source

What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors? – Protocol of a systematic review

BMC Medical Genetics, 2004
Background The Angiotensin Converting Enzyme (ACE) insertion/deletion (I/D) polymorphism has received much attention in pharmacogenetic research because observed variations in response to ACE inhibitors might be associated with this polymorphism ...
Steurer J, Puhan MA, Scharplatz M, Bachmann LM   +3 more
doaj   +1 more source

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND PROTEINURIA

Zdravniški Vestnik, 2002
Background. In numerous clinical studies that tried to identify risk factors for progressive renal function loss, the severity of proteinuria correlated with the rate of renal function loss.
Tanja Kök, Radovan Hojs
doaj  

Medicines in the rehabilitation of patients after myocardial infarction: angiotensin-converting enzyme inhibitors

КардиоСоматика, 2010
The paper analyzes the use of angiotensin-converting enzyme (ACE) inhibitors in patients after prior myocardial infarction. It presents the data of controlled studies, which indicate that it is warranted to use ACE inhibitors to improve prognosis in ...
A. S Galyavich
doaj  

Pleiotropic ACE inhibitor effects: any benefits for sulfhydryl agents?

Кардиоваскулярная терапия и профилактика, 2008
Clinical pharmacology of ACE inhibitors is described, comparing pharmacological effects of agents with or without sulfhydryl groups in their molecules. Sulfhydryl group-containing ACE inhibitors – captopril and especially zofenopril – are characterized ...
D. V. Preobrazhensky, B. A. Sidorenko, S. A. S.A. Pataraya, A. V. Skorik   +3 more
doaj  

ACE inhibitors and the risk of lung cancer-is there causality? [PDF]

Br J Cancer, 2023
Strauss MH, Sipahi I, Hall AS.
europepmc   +1 more source